{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T13:33:52Z","timestamp":1791380032898,"version":"4.3.3"},"reference-count":39,"publisher":"MedWorks Media","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychopharmacol Bull"],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>This study examines how inpatients with catatonia responded when treated with or without antipsychotic medications. It employs two metrics to account for both the catatonic symptoms and the more traditionally psychotic symptoms. Length of stay is a secondary metric.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The primary investigator retrospectively collected data on 164 patients diagnosed with catatonia on an academic inpatient service from July 2018 through September 2023. The treatments of these patients were separated into two distinct categories: Group A (n = 81) received antipsychotic medication with benzodiazepines and\/or electroconvulsive therapy, and Group B (n = 83) received benzodiazepines and\/or electroconvulsive therapy without antipsychotics. Scores on admission from the Bush Francis Catatonia Rating Scale and positive symptom subscale from the Positive and Negative Syndrome Scale were collected and compared with scores at discharge. ANOVA analysis was used to compare outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The antipsychotic-treated group demonstrated significantly higher Bush Francis Catatonia Rating Scale scores (p &lt; 0.0001) and positive scale of the Positive and Negative Syndrome Scale scores (p &lt; 0.0001) at discharge than the group receiving only benzodiazepines and\/or electroconvulsive therapy. Patients hospitalized multiple times and treated under both conditions were used as their own controls. Bush Francis Catatonia Rating Scale scores (p &lt; 0.0001) and positive scale of the Positive and Negative Syndrome Scale scores (p &lt; 0.0001) were higher at discharge when antipsychotics were added to treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Patients treated without antipsychotics showed greater improvement in both their traditional catatonic symptoms and in their psychotic symptoms.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.64719\/pb.18513","type":"journal-article","created":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T08:56:35Z","timestamp":1780995395000},"page":"31-46","source":"Crossref","is-referenced-by-count":0,"title":["Catatonia Associated with Psychosis: A Retrospective Study of 164 Inpatients"],"prefix":"10.64719","volume":"56","author":[{"given":"Timothy R","family":"Moore","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara D","family":"Almeyda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward K","family":"Silberman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerrin R","family":"Peter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mindy M","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashida","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54175","published-online":{"date-parts":[[2026,6,4]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Fink M, Taylor MA. Catatonia: a clinician\u2019s guide to diagnosis and treatment. 2003 Cambridge University Press.","DOI":"10.1017\/CBO9780511543777"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Shorter E, Fink M. The madness of fear: a history of catatonia. 2018 Oxford University Press.","DOI":"10.1093\/med\/9780190881191.001.0001"},{"key":"ref3","unstructured":"Kraepelin E, Diefendorf AR. Clinical psychiatry: a textbook for students and physicians. 1904 Macmillan & Co."},{"key":"ref4","unstructured":"Schneider K. Clinical psychopathology. Hamilton MW, translator. 1959 Grune & Stratton."},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Bell L. On a form of disease resembling some advanced stages of mania and fever, but so contradistinguished from any ordinary observed or described combination of symptoms as to render it probable that it may be overlooked and hitherto unrecorded malady. Am J Insanity. 1849;6:127.","DOI":"10.1176\/ajp.6.2.97"},{"key":"ref6","unstructured":"Kahlbaum KL. Catatonia. 1973 Johns Hopkins University Press."},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Rasmussen SA, Mazurek MF, Rosebush PI. Catatonia: Our current understanding of its diagnosis, treatment and pathophysiology. World J Psychiatry. 2016;6(4):391\u2013398.","DOI":"10.5498\/wjp.v6.i4.391"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Taylor MA, Fink M. Catatonia in psychiatric classification: a home of its own. Am J Psychiatry. 2003;160:1233\u20131241.","DOI":"10.1176\/appi.ajp.160.7.1233"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Kruger S, Cooke RG, Spegg CC, Braunig P. Relevance of the catatonic syndrome to the mixed manic episode. J Affect Disord. 2003;74:279\u2013285.","DOI":"10.1016\/S0165-0327(02)00088-5"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Starkstein SE, Petracca G, Teson A et al. Catatonia in depression: prevalence, clinical correlates, and validation of a scale. J Neurol Neurosurg Psychiatry. 1996;60:326\u2013332.","DOI":"10.1136\/jnnp.60.3.326"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Rosebush PI, Mazurek MF. Catatonia and its treatment. Schizophr Bull. 2010;36(2):239\u2013242.","DOI":"10.1093\/schbul\/sbp141"},{"key":"ref12","unstructured":"Rosebush PI, Hildebrand AM, Furlong BG, Mazurek MF. Catatonic syndrome in a general psychiatric inpatient population: Frequency, clinical presentation, and response to lorazepam. J Clin Psychiatry. 1990;51(9):357\u2013362."},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Lee J, Schwartz D, Hallmayer J. Catatonia in a psychiatric intensive care facility: Incidence and response to benzodiazepines. Ann of Clinical Psychiatry. 2000;12(2):89\u201396.","DOI":"10.3109\/10401230009147094"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Tang VM, Park H. Brief episodes of non-specific psychosis later diagnosed as periodic catatonia. BMJ Case Rep. 2016;2016:bcr2016218178.","DOI":"10.1136\/bcr-2016-218178"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"England ML, Ong\u00fcr D, Konopaske GT, Karmacharya R. Catatonia in psychotic patients: Clinical features and treatment response. J Neuropsychiatry Clin Neurosci. 2011;23(2):223\u2013226.","DOI":"10.1176\/appi.neuropsych.23.2.223"},{"key":"ref16","unstructured":"Winokur G, Clayton PJ, Reich T. Manic Depressive Illness. 1969 C. V. Mosby."},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"White DAC, Robins AH. Catatonia: Harbinger of the neuroleptic malignant syndrome. Br J Psychiatry. 1991;158(3):419\u2013421.","DOI":"10.1192\/bjp.158.3.419"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Yacoub A, Francis A. Neuroleptic malignant syndrome induced by atypical neuroleptics and responsive to lorazepam. Neuropsychiatr Dis Treat. 2006;2(2):235\u2013240.","DOI":"10.2147\/nedt.2006.2.2.235"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Bush G, Fink M, Petrides G, Dowling F, Francis A. Catatonia. I. Rating scale and standardized examination. Acta Psychiatr Scand. 1996;93(2):129\u2013136.","DOI":"10.1111\/j.1600-0447.1996.tb09814.x"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261\u2013276.","DOI":"10.1093\/schbul\/13.2.261"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Ungvari GS, Leung CM, Wong MK, Lau J. Benzodiazepines in the treatment of catatonic syndrome. Acta Psychiatr Scand. 1994;89(4):285\u2013288.","DOI":"10.1111\/j.1600-0447.1994.tb01515.x"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Segal J, Isaacs MD, Berk M. Neuroleptic malignant syndrome: possible induction by olanzapine in a case with relapsing catatonia. Int J Psychiatry Clin Pract. 2001;5(3):211\u2013213.","DOI":"10.1080\/136515001317021699"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Beach SR, Gomez-Bernal F, Huffman JC, Fricchione GL. Alternative treatment strategies for catatonia: a systematic review. Gen Hosp Psychiatry. 2017;48:1\u201319.","DOI":"10.1016\/j.genhosppsych.2017.06.011"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Redon M, Virolle J, Montastruc F et al. The use of antipsychotics in the treatment of catatonia: a systematic review. Eur Psychiatry. 2025;68(1):e48. doi: 10.1192\/j.eurpsy.2025.9.","DOI":"10.1192\/j.eurpsy.2025.9"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Lingjaerde O. Benzodiazepines in the treatment of schizophrenia: an updated survey. Acta Psychiatrica Scandinavica. 1991;84(5):453\u2013459.","DOI":"10.1111\/j.1600-0447.1991.tb03177.x"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Edinoff AN, Kaufman SE, Hollier JW et al. Catatonia: clinical overview of the diagnosis, treatment, and clinical challenges. Neurol Int. 2021;13(4):570\u2013586.","DOI":"10.3390\/neurolint13040057"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Rybakowski JK. 120th anniversary of the kraepelinian dichotomy of psychiatric disorders. Curr Psychiatry Rep. 2019;21(8):65. doi: 10.1007\/s11920-019-1048-6.","DOI":"10.1007\/s11920-019-1048-6"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Schwartz T, Stahl S. Treatment strategies for dosing the second-generation antipsychotics. CNS Neurosci Ther. 2011;12(2):110\u2013117.","DOI":"10.1111\/j.1755-5949.2011.00234.x"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"DaCosta J, Very E, Rousseau V et al. Comparative effects of 30 antipsychotics on risk of catatonia: an analysis of the WHO pharmacovigilance database. J Clin Psychiatry. 2023;84(1):21m14238.","DOI":"10.4088\/JCP.21m14238"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Sienaert P, Dhossche DM, Vancampfort D, De Hert M, Gazdag G. A clinical review of the treatment of catatonia. Front Psychiatry. 2014;5:181.","DOI":"10.3389\/fpsyt.2014.00181"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"Caroff SN, Ungvari GS, Gazdag G. Treatment of schizophrenia with catatonic symptoms: a narrative review. Schizophr Res. 2024;263:265\u2013274. doi: 10.1016\/j.schres.2022.11.015.","DOI":"10.1016\/j.schres.2022.11.015"},{"key":"ref32","unstructured":"The Centers for Medicare & Medicaid Services (CMS) Medicaid Integrity Group (MIG) Atypical Antipsychotic Medications: use in adults. 2015 In The Centers for Medicare & Medicaid Services (CMS) Medicaid Integrity Group (MIG) https:\/\/www.cms.gov\/Medicare-Medicaid-Coordination\/Fraud-Prevention\/Medicaid-Integrity-Education\/Pharmacy-Education-Materials\/atyp-antipsych-education.html."},{"key":"ref33","unstructured":"Caroff S. The neuroleptic malignant syndrome. J Clin Psychiatry. 1980;41:79\u201383."},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Regestein G, Alpert J, Reich P. Sudden catatonic stupor with disastrous outcome. JAMA. 1977;238:618\u2013620.","DOI":"10.1001\/jama.1977.03280070058025"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"Addonizio G, Susman VL, Roth SD. Symptoms of neuroleptic malignant syndrome in 82 consecutive inpatients. Am J Psychiatry. 1986;143(12):1587\u20131590. doi: 10.1176\/ajp.143.12.1587.","DOI":"10.1176\/ajp.143.12.1587"},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"White DA, Robins AH. Catatonia: harbinger of the neuroleptic malignant syndrome. Br J Psychiatry. 1991;158:419\u2013421. doi: 10.1192\/bjp.158.3.419.","DOI":"10.1192\/bjp.158.3.419"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Pope HG, Jr, Cole JO, Choras PT, Fulwiler CE. Apparent Neuroleptic Malignant Syndrome with Clozapine and Lithium. The Journal of Nervous and Mental Disease. 1986;174(8):493\u2013495.","DOI":"10.1097\/00005053-198608000-00010"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Gelenberg AJ, Mandel MR. Catatonic reactions to high potency neuroleptic drugs. Arch Gen Psychiatry. 1977;34:947\u2013950.","DOI":"10.1001\/archpsyc.1977.01770200085010"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988;45(9):789\u2013796.","DOI":"10.1001\/archpsyc.1988.01800330013001"}],"container-title":["Psychopharmacology Bulletin"],"original-title":[],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:37:06Z","timestamp":1791315426000},"score":1,"resource":{"primary":{"URL":"https:\/\/medworksmedia.com\/pb-article\/catatonia-associated-with-psychosis-a-retrospective-study-of-164-inpatients\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,4]]},"references-count":39,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,6,4]]}},"URL":"https:\/\/doi.org\/10.64719\/pb.18513","relation":{},"ISSN":["2472-2448"],"issn-type":[{"value":"2472-2448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,4]]}}}